Correction of anemia syndrome in patients with malignant lymphomas

Summary. Anemia is one of the most common symptoms associated with malignant tumors. The paper presents current recommendations for erythropoiethin therapy for correction of chemotherapy-induced anemia in patients with malignant neoplastic process. The analysis of the effectiveness of erythropoiethin (Epobiokrin, produced by «Biopharma») was carried out in patients with non-Hodgkin’s and Hodgkin’s lymphoma who received chemotherapy.